Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

f 2008 and if the results of this trial are positive, Cadence submitting a new drug application (NDA) for Omigard in the first half of 2009; data from the celgosivir Phase II extension protocol being available by the end of 2007; 4-week interim results from the Phase II viral kinetics combination study of celgosivir in approximately 10 treatment-naive patients in October 2007; submitting an IND in the US in the first quarter of 2008 for the future development of celgosivir; Cutanea Life Sciences completing the Phase II CLS001 rosacea clinical trial in 2007; our estimate of the probable royalties payable to the holders of the convertible royalty participation units; the Company continuing to advance its highest priority programs while operating within an annual burn rate of $11 million to $13 million; and the Company's financial resources being sufficient to fund operations into the third quarter of calendar 2008.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: Cadence's ability to enroll sufficient patients to complete the Omigard CLIRS trial; the adequacy of the CLIRS trial design to generate data that are deemed sufficient by regulatory authorities to support potential regulatory filings, including an NDA, for Omigard; our ability to manage licensing opportunities; our ability to initiate, fund and complete non-clinical studies, clinical studies, manufacturing and all ancillary activities within our expected timelines; our partner Cutanea Life Sciences completing a Phase II CLS001 rosacea clinical trial in 2007; to and future expense levels being within our current expectations.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and other factors including: dependence on c
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer health ... EmblemHealth , the New York -based ... RedBrick Compass health assessment, combined with the RedBrick Journeys ... EmblemHealth is among the first health plans in the ...
(Date:1/15/2014)... 15, 2014 A study has been launched ... Formula 1 track could help to tackle the problem of ... Stowhealth (a GP surgery based in Stowmarket) and academics at ... Telemetry technology, which is inspired by equipment used ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... As open ... at leading industry events. , ... Washington, DC (PRWEB) June 11, 2010 -- Open source software will be a featured topic ... Meeting is the premier event for professionals involved in the discovery, development, and life ...
... 11 PRA International, a leading Clinical Research Organization, is exhibiting ... 15th congress in Barcelona 10-13 June 2010 . , ... At PRA,s booth (#202), conference ... M.D., to discuss the key issues and latest developments in hematology drug ...
... , FORT WORTH, Texas , ... of a new educational module "Exploring Biofilms," an,accredited, online course designed ... play in chronic wound infections. , ... "Bacterial biofilms are a ...
Cached Biology Technology:Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting 2Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting 3PRA International Exhibits at European Hematology Association Congress 2The Wound Institute(R) Launches Educational Course on Bacterial Biofilms 2The Wound Institute(R) Launches Educational Course on Bacterial Biofilms 3The Wound Institute(R) Launches Educational Course on Bacterial Biofilms 4
(Date:4/17/2014)... that devastate honeybees in Europe, Asia and the United ... appear to be impacting native honeybee populations at this ... invasive pests include including Nosema microsporidia and ... to be resilient to these invasive pests, which suggests ... in Europe, Asia and the United States currently are ...
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... Researchers from the University of Georgia College of ... that could open new avenues for treating Ichthyophthirius ... that commonly attacks freshwater fish. With the ... harbors two apparently symbiotic intracellular bacteria: Bacteroides, ...
... turns out that wearing a cap is good for you, ... from the Johns Hopkins Engineering in Oncology Center have shown ... holds the cell,s nucleus, its genetic storehouse, in its proper ... the researchers say, could provide clues to the diagnosis and ...
... Calif., Dec. 2 DigitalPersona, Inc., a leader in ... with IBM to deploy a new model of its ... systems. The DigitalPersona U.are.U® 4500HD offering allows point-of-sale applications ... specific transactions can be linked to the individuals who ...
Cached Biology News:UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 3A cell's 'cap' of bundled fibers could yield clues to disease 2DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2
Immunogen: VDAC3 Protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
TRBP1 Antibody...
Complete cell culture media with cytokines...
Collected from sexually mature, mixed sex, mixed breed cats. Physiochemical constituents are measured to ensure lot-to-lot consistency....
Biology Products: